Evotec is expected to apply its integrated and innovative drug discovery platform in combination with its disease biology expertise against targets nominated by Genentech. This will include assay development and high throughput screening, medicinal chemistry and structural biology.
The aim of the collaboration is to deliver high quality leads and development candidates to support Genentech’s research efforts.
Werner Lanthaler, CEO of Evotec, said: “We are proud that Genentech has selected Evotec’s scientists and drug discovery platform to support their research efforts. We look forward to working closely with Genentech’s scientists and achieving success together.”
Genentech is a biotechnology company that discovers, develops, manufactures and commercialises medicines for patients with serious or life-threatening medical conditions.